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ABSTRACT:  Endocrine  dysfunction  in  Thalassaemia  major  (TM)  is  a  common  and 
disturbing complication, which requires prompt recognition and treatment. The contribution 
of  the  underlying  molecular  defect  in  TM  to  the  development  of  endocrinopathies  is 
significant because the patients with the more severe genetic defects have a greater rate of 
iron loading through higher red cell consumption. TM patients frequently present delay of 
growth  and  puberty with  reduction of  final height.  The  pathogenesis  of  growth failure  is 
multifactorial and is mainly due to chronic anemia and hypoxia, chronic liver disease, zinc 
and folic acid deficiency, iron overload, intensive use of chelating agents, emotional factors, 
and endocrinopathies (hypogonadism, delayed puberty, hypothyroidism) and GH-IGF-1 axis 
dysregulation.  Although  appropriate  iron  chelation  therapy  can  improve  growth  and 
development, TM children and adolescents treated intensively with desferrioxamine remain 
short as well, showing body disproportion between the upper and lower body segment. Body 
disproportion  is  independent  of  pubertal  or  prepubertal  period  of  greater  height  gain. 
Treatment with recombinant GH (rhGH) is recommended when GH deficiency is established, 
and even so, the therapeutic response is often non satisfactory. Growth acceleration is mostly 
promoted with sex steroids in children with associated pubertal delay. Sexual complications in 
TM,  which  include  Delayed  Puberty,  Arrested  Puberty  and  Hypogonadism,  present  the 
commonest  endocrine  complication.  Iron  deposition  on  gonadotroph  cells  of  the  pituitary 
leads to disruption of gonadotrophin production which is proven by the poor response of FSH 
and LH to GnRH stimulation. In the majority of patients gonadal function is normal as most 
women with Amenorrhea are capable of achieving pregnancy with hormonal treatment and 
similarly men with azoospermia become fathers. Secondary Hypogonadism appears later in 
life,    and is manifested in women as Secondary Amenorrhea and in men as decline in sexual 
drive and azzoospermia. The damage to the hypothalamus and pituitary is progressive, even 
when intensive chelating therapy is given and the appearance of Hypogonadism in both sexes 
is often unavoidable. Close follow up and proper management is crucial for every patient with 
TM. Early recognition of growth disturbance and prevention of hypogonadism by early and Medit J Hemat Infect Dis 2009; 1; Open Journal System www.mjhid.org/article/view/4612
judicious chelation therapy is mandatory for the improvement of their quality of life. Patients 
with TM can now live a better life due to modern advances in their medical care and our 
better  understanding  in  the  pathogenesis,  manifestation  and  prevention  of  endocrine 
complications.
Preface:  Treatment  of  beta-Thalassaemia  Major 
(TM)  is  based  on  regular  blood  transfusions  to 
maintain  the  pre-transfusional  Hb  level  above  9 
gr/dl and appropriate chelation therapy to avoid the 
consequences of iron  overload. The  metabolically 
active iron catalyses the formation of free radicals, 
which  damage  membrane  lipids  leading  to  cell 
death and eventually organ failure. The endocrine 
glands are particularly vulnerable to the excess iron, 
so that the appearance of endocrine dysfunction in 
Thalassaemia  major  is  a  common  and  disturbing 
complication,  which  requires  prompt  recognition 
and treatment.  The contribution of the  underlying 
molecular  defect  in  TM  to  the  development  of 
endocrinopathies  and  particularly 
Hypogonadotrophic  Hypogonadism  is  significant 
because the patients with the more severe genetic 
defects have a greater rate of iron loading through 
higher red cell consumption.
1
Growth: TM  patients  frequently  present delay  of 
growth and puberty with reduction of final height. 
Growth failure in TM has been recognised for many 
years,  and  has  persisted  despite  major  treatment 
advances.  The  child  with  TM  has  a  particular 
growth pattern, which is relatively normal until age 
9-10 years; after this age a slowing down of growth 
velocity and  a  reduced  or absent  pubertal  growth 
spurt  are  observed.  The  growth  plate  fusion  is 
usually delayed until the end of the second decade 
of  life.
2 The  pathogenesis  of  growth  failure  is 
multifactorial
3,4 and is mainly due to chronic anemia 
and hypoxia, chronic liver disease, zinc and folic 
acid  deficiency,  iron  overload,  intensive  use  of 
chelating  agents,  emotional  factors,  endocrine-
pathies  (hypogonadism,  delayed  puberty,  hypo-
thyroidism) and GH-IGF-1 axis dysregulation. 
Chronic  hypoxia  is  no  longer  a  contributing 
factor nowadays in properly treated children. Linear 
growth  in  childhood  is  disrupted  only  in  a  small 
percentage  of  children  due  to  anemia,  ineffective 
erythropoiesis  and  iron  overload.  During  the  first 
decade  of  life  the  maintenance  of  haemoglobin
levels  above  9  g/dL  together  with  adequate  iron 
chelation  therapy  makes  the  children  with  TM 
indistinguishable  from  their  non  thalassaemic 
peers.
5,6
Zinc deficiency is probably a concomitant factor 
in  growth  failure. The  effects  of  zinc 
supplementation on growth velocity were assessed 
in  22  patients  with  biochemical  evidence  of  zinc 
deficiency.  The  mean  height  velocity  of  zinc 
supplemented children was significantly greater that 
of  normal  children
7.  The  crucial  role  of  zinc 
deficiency  however  was  not  confirmed  by  other 
studies.
8,9
It is well known that high serum ferritin levels 
during the first decade of life are associated with 
final  short  stature
10,11,  indicating  that  appropriate 
iron  chelation  therapy  can  prevent  or  limit  this 
complication.  However,  several  studies  showed 
high prevalence of short stature in TM children and 
adolescence  treated  intensively  with 
desferrioxamine (DFX).
4,12,13 In addition, premature 
chelating therapy, between ages of 2-5 years, may 
have deleterious  effects  on  growth.
12,14,15 DFX  is 
proven to inhibit cell proliferation, DNA synthesis, 
collagen  formation  and  trace  mineral  deposition 
such  as  cooper  and  zinc.  Mineral  depletion  may 
result in a decrease of alkaline phosphatase activity. 
This  complex  mechanism  results  in 
platyspondylosis  with  flattening  of  the  vertebral 
bodies  and  consequent  shortening  of  the  spinal 
height, resulting in truncal shortening , also in the 
presence of normal stature.
1,2,15-20
Body  disproportion  between  the  upper  (short) 
and  lower  body  segment  (normal)  is  observed  in 
approximately  15-40%  of  TM  patients.
18 Spinal 
growth  impairment  starts  during  infancy  and 
deteriorates  progressively.  Most  Thalassaemics, 
especially males do not reach their target height and 
their  Sitting  height  is  more  severely  affected 
(Figure  1).  During puberty  hypogonadism further 
impairs spinal growth (Figure 2). 
Figure  1.  Standing  and  Sitting  Final  Height  SDS  in  adult 
patients with Thalassaemia of both sexes.Medit J Hemat Infect Dis 2009; 1; Open Journal System www.mjhid.org/article/view/4612
Figure  2.  Standing  and  Sitting  Height  SDS  in  different  age 
groups in children with Thalassaemia of both sexes.
Sex  steroids  replacement  therapy  cannot 
adversely  affect  body  disproportion,  as  no 
difference has been observed in pubertal growth and 
final height between treated Hypogonadal patients 
compared  to  those  with  spontaneous  puberty  and 
truncal  shortening  at  final  height  is  evident  in 
patients  with  either  spontaneous  or  induced 
puberty.
17 Body  disproportion  therefore  is 
independent  of  pubertal  or  prepubertal  period  of 
greater  height  gain.  Decrease  in  upper/lower 
segment  ratio  has  been  reported  in  patients  who 
have  been  poorly  chelated  during  childhood  and 
adolescence,  so  that  other  contributing  factors 
besides  chelation  therapy  or  the  disease  itself 
influence spinal growth.
21
The hormonal cause of growth retardation in TM 
children  is  complex.  Besides  hypogonadism  and 
hypothyroidism it has been apparent that GH-IGF-1 
axis  plays  a role  in  their  abnormal  growth.
22
Evaluation  of  GH-IGF-1  axis  has  given 
contradictory  results.  The  response  of  GH  to 
stimulation tests has been found to be normal
23,24 or 
reduced with a variable prevalence
4,25-33 in a number 
of TM patients with short stature. De Sanctis et al
reported 3.1% of thalassemics to have GHRH-GH-
IGF  axis  dysfunction.
21 The  presence  of  GH 
neurosecretory  dysfunction  is  supported  by  the
impaired  24  hour  GH  secretion
29,34-37 due  to 
hypothalamic or pituitary dysfunction. The anterior 
pituitary  is  particularly  sensitive  to  free  radical 
oxidative stress. MRI of pituitary shows that even a 
modest  amount  of  iron  deposition  within  the 
anterior  pituitary can  interfere  with  its  function
38. 
Sex  hormones  play  an  important  role  in  pubertal 
growth spurt and TM patients with delayed puberty 
do not exhibit normal growth spurt; their GH peak 
amplitude is reduced as well as their nocturnal GH 
levels.
26,34,39 Several authors have reported normal 
GH and GHBP levels but low levels of IGF-1 and 
IGFBP-3  which  are  not  properly  increased  with 
IGF-1 generation test, suggesting that insensitivity 
to  GH  action  may  be  the  cause  of  abnormal 
growth.
20,25,28,32,40-42 However, a lack of correlation 
between  IGF-1, IGFBP-3  and  height  SDS in  TM 
children  with  growth  failure  may  indicate  that 
growth failure is not specifically related to GH-IGF-
1  axis.  There  is  a  possibility  that  DFX  and  iron 
loading at the growth plate have a deleterious effect 
in  local  IGF-1  production  and  growth 
regulation.
43,44
Can children with TM attain normal stature and 
develop  normally  with early and reasonable DFX 
treatment? Although iron chelation can decrease the 
frequency of endocrinopathies, early DFX treatment 
may result in growth impairment. On the other hand 
poor compliance with DFX may eventually lead to 
severe  iron  burden,  gonadal  dysfunction  and 
eventually growth failure. The benefits of treatment 
should  be  weighted  against  the  potential  adverse 
effects  and  the  caring  physician  should  balance 
between  the  efficacy  and  the  injudicious  use  of 
DFX.  An  ideal  therapeutic  regimen,  which  will 
avoid the toxic effects of iron overload and that of 
continuous subcutaneous chelation therapy, has yet 
to  be  found.  It  is  therefore  recommended  that 
growth in both standing and sitting position should 
be assessed at 6-month intervals in order to detect 
early growth failure. Long-term observations on the 
effect of therapy are needed before this mysterious 
puzzle is solved. Alternative oral chelation agents 
are  often  an  option  in  cases  of  DFX  toxicity, 
although  some  bone  lesions  remain  irreversible. 
Prevention  of growth  retardation  is  essential. 
Monitoring growth in all children by using growth 
charts  for  both  standing  and  sitting  height  is 
mandatory. The  mean hemoglobin  levels must be 
kept near 9 gr/dl. Prompt initiation of iron chelation 
therapy prevents pituitary haemosiderosis, which is 
the main cause of GH insufficiency. 
Treatment  with  recombinant  GH  (rhGH)  is 
recommended  when  GH  deficiency  is 
established.Therapeutic  response  with  rhGH 
administration in cases with GH deficiency, is often 
non satisfactory. In poor responders such treatment 
should be discontinued. Treatment with rhGH for 1 
year  seems  to  be  effective  in  increasing  growth 
velocity  without  causing  adverse  effects  on  bone 
maturation,  glucose  tolerance,  serum  lipids  and 
blood  pressure.
45-52 The  encouraging  results 
described during the first year of rhGH treatment do Medit J Hemat Infect Dis 2009; 1; Open Journal System www.mjhid.org/article/view/4612
not  persist during the  second and the third years. 
This is because increase in bone age with continued 
treatment  is  equal  to  or  slightly  greater  than  the 
height age increase
49. Prolonged therapy with rhGH 
could not improve final height; on the contrary a 
negative  effect  may  be  hypothesized
52.  Growth 
acceleration is mostly promoted with sex steroids in 
children  with  pubertal  delay  as  sexual 
complications  present  a  significant  issue  in 
Thalassaemics. 
Protocol  for  investigation  of  Thalassaemic 
children: 
1.  Measure  current  height  both  standing  and 
sitting and plot on the growth chart. Calculate the 
target  height  based  on  parental  heights.  Compare 
with previous measurement to estimate the growth 
velocity.  Examine  pubertal  status.  Note  any 
physical  disproportion.  Review  emotional  and 
social status.
2. Assess bone maturation
3.  Routine  blood  tests  including  liver  function 
tests, ferritin, biochemical profile, and zinc
4. Urine analysis
5. Thyroid function tests (Free T4, TSH)
IFG-1 and IGFBP-3 
Stimulation tests to assess GH secretion, where 
at  least  two  tests  are  required.  Priming  with  sex 
steroids (testosterone depot 100 mg IM in boys and 
Ethinyl Estradiol 10 mcg orally for 3 days in girls 
72hrs before test may be necessary in children who 
are prepubertal and have a bone age of 10 years.
IGF-1 generation test in patients with low levels 
of IFG-1 and IFGBP-3 and normal GH secretion to 
exclude GH resistance. 
Puberty is  the  period  of  life  that leads  to 
adulthood  through  dramatic  physiologic  and 
psychologic changes. It is the period during which 
physical and hormonal changes occur such that the 
capability of sexual reproduction is attained. This 
biological phenomenon, which is the result of the 
activation  of  the  Hypothalamic  – Pituitary  –
Gonadal  axis  and  clinically  manifested  by  the 
appearance of sexual characteristics comprises this 
unique and integrated transition from childhood to 
young adulthood. 
Sexual  complications  in  TM  present  the 
commonest  endocrine  complication  in  almost  all 
studies (Table 1). These include: Delayed Puberty, 
Arrested  Puberty  and  Hypogonadism.  Delayed 
puberty is defined as the absence of any pubertal 
sign  in   girls  (breast  enlargement)  and  in  boys 
(testicular  enlargement)  by  the  age  of  13  and  14 
years respectively. Delayed puberty in TM is almost 
always due to Hypogonadotrophic Hypogonadism, 
which  still  remains  the  most  stressful 
complication.
53 Iron  deposition  on  gonadotrophic 
cells  of  the  pituitary  leads  to  disruption  of 
gonadotrophin production which is  proven by the 
poor response of FSH and LH to GnRH stimulation 
and  clinically  manifested  as  Hypogonadotrophic 
Hypogonadism  (Figures  3,  4).  Women  have 
Primary  Amenorrhea  and  additional 
endocrinopathies  have  a  completely blunted 
response  to  GnRH  test  indicating  the  severity  of 
haemosiderosis.  Anterior  pituitary  function 
correlates  well  with  tissue  iron  deposition  in  the 
pituitary  gland,  as  quantitatively  determined  by 
MRI measurements (T2*).
38,54 However, there is no 
correlation between MRI measurements, the GnRH 
stimulation  test  and  the  clinical  status  of  the 
patients
38. 
Figure 3. FSH levels after GnRH stimulation in Thalassaemic 
women  with  Normal  menstrual  cycles  (NM),  Primary 
Amenorrhea  (PA),  Primary  Amenorrhea  with  additional 
endocrinopathies  (PA+)  and  Secondary  Amenorrhea  (SA).X-
axis: time in minutes, y-axis: FSH  in miu/l
The  association  of  susceptibility  to  develop 
Hypogonadotrophic  Hypogonadism  with  the 
genotype  has  already  been  proven.
1,55,56 The 
contribution of the underlying molecular defect in 
TM to the development of endocrinopathies in TM 
and particularly Hypogonatotrophic Hypogonadism 
is  significant,  because  the  patients  with  the  more 
severe defects have a greater rate of iron loading 
through higher red cell consumption and probably a 
different vulnerability to free radical damage.
1,55
Hypogonatotrophic  hypogonadism  in 
Thalassaemia is related not only to iron toxicity on
gonadotroph cells but also to iron toxicity on the 
adipose tissue thus changing the physiological role 
of leptin in sexual maturation and fertility. Leptin
is  a  polypeptide  hormone  that  is  produced  in  fat 
cells due to the expression of the ob gene. In girls
leptin  levels  increase  dramatically  as  puberty 
develops and stimulate the Hypothalamic-Pituitary-
Gonadal axis.
57,58Medit J Hemat Infect Dis 2009; 1; Open Journal System www.mjhid.org/article/view/4612
Table 1: Prevalence of endocrine complications in patients with Thalassaemia in Cyprus, other countries and in the TIF multicenter 
study.
30
Figure 4. LH levels after GnRH stimulation in Thalassaemic 
women  with  Normal  menstrual  cycles  (NM),  primary 
Amenorrhea  (PA),  Primary  Amenorrhea  with  additional 
endocrinopathies (PA+) and Secondary Amenorrhea (SA). - x-
axis xtime in minutes, y-axis:LH  in miu/l 
There  is  evidence  that  this  hormone  acts  as  a 
permissive signal allowing puberty to precede. The 
impaired  synthesis  of  leptin  in  Thalassaemic 
patients seems to be related to transferrin receptor 
levels  and  therefore  iron  toxicity  but  further 
research will  be  required to elucidate this  critical 
issue
59,60.  Gonadal  iron  deposition  occasionally 
occurs. The iron deposition on the gonads is a rarer 
condition.  In  the  majority  of  patients  gonadal 
function  is  normal  as  most  women  with 
Amenorrhea  are  capable  of  ovulating  with 
hormonal  treatment  and  similarly  men  with 
azoospermia become fathers. 
Arrested  puberty  is  defined  as  the  absence  of 
further  pubertal  progression  -once  puberty  has 
started  -for  more  than  one  year,  where  testicular 
volume in boys never exists 6 to 8 ml and breast 
size in girls remains unchanged. Failure of sexual 
development by the age of 15 to 16 years in both 
sexes  is  defined  as  Hypogonadism.  Secondary 
Hypogonadism  appears  later  in  life,    and  is 
manifested  in  women  as  Secondary  Amenorrhea 
and  in  men  as  decline  in  sexual  drive  and 
azzoospermia. 
Adolescent  girls  with  TM  often  present  with 
Primary Amenorrhea and boys fail to become well 
virilized.  The  damage  to  the  hypothalamus  and 
pituitary  is  progressive,  even  when  intensive 
chelating  therapy  is  given  and  the  appearance  of 
Hypogonadism  in  both  sexes  is  often 
unavoidable
1,55,61. Most women with TM manifest 
Secondary Amenorrhea at some stage in their life 
and men develop hypogonadism in their 3
rd decade 
after  being  normal  for  some  years  and  even 
becoming fathers.
55,62,63
The  overall  frequency  of  bone  disease  in 
hypogonadal  patients  with  TM  is  increased 
compared  with  those  of  normal  gonadal 
function
1,64. Sex  steroids  regulate  skeletal 
maturation  and  preservation  in  both  men  and 
women,  therefore  the  impact  of  gonadal 
insufficiency on skeletal integrity has been widely 
recognised in both genders. BMD normally rises at 
a steady rate throughout childhood until around the 
age of 12, and then there is a sudden acceleration of 
bone  mineral  accretion  which  coincides  with  the 
onset  of  puberty  and  the  pubertal  growth  spurt. 
Failure  to  progress  normally  through  puberty  is 
associated with failure of achievement of peak bone 
mass, which is a contributing factor to the ultimate 
bone disease in Thalassaemia.
44,65,66
Study Cyprus Greece 
1995 
74 Italy 1995 
53 N. America 
2004 
75 TIF       2004 
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N
o of patients 435 262 1861 342 3817
Hypogonadism 32.5 42 49 35 40.5
Short Stature 35 32 ---- ---- 30.8
Short Sitting height 72 ---- ---- ---- ----
Hypothyroidism 5.9 4 6.2 9 3.2
Hypoparathyroidism 1.2 4 3.6 4 6.9
DM/IGT 9.4 5/27 4.9 10 3.2/6.5Medit J Hemat Infect Dis 2009; 1; Open Journal System www.mjhid.org/article/view/4612
Protocol for investigation of pubertal disorder: 
The absence of any clinical pubertal signs in a boy 
(testicular enlargement) older that 14 years and in a 
girl  (breast  development)  older  than  13  years 
requires investigation. 
Measure Testosterone in the boy and Oestradiol 
in the girl. DHEA-S in both sexes is often helpful 
Perform the GnRH test to evaluate the pituitary 
capacity to secrete the gonadotropins FSH and LH, 
where the response in Hypogonadism is low 
Bone  age is  helpful  for  the  treatment  decision 
options 
Therapeutic approach in delayed puberty should 
mimic biological and biochemical pubertal changes, 
aiming on promotion of linear growth as well.
67-70
Induction  of  puberty  in  boys  can  be  achieved 
with Testosterone depot   IM 25-50mg monthly for 
6 months and reassessment. Pubic hair will appear 
and penile size will increase. Increase in   testicular 
volume indicates activation of the axis and release 
of Gonadotrophins (FSH and LH), where no further 
treatment is needed except for close observation. In 
case  where  testicular  size  is  unchanged,  then 
treatment  is  continued  for  6  months  and 
subsequently  the  dose  is  increased  to  100  mg 
monthly  for  one  year.  Therapeutic  schedule  is 
determined  by  the  growth  potential,  clinical 
response  and  emotional  factors.  For  testicular 
enlargement, the therapeutic regime is altered to the 
combination of hCG and hMG or recFSH, both of 
which  mimic  the  pituitary  Gonadotrophins.  The 
final  adult dose  of Testosterone depot, is  always 
individualized  and  usually  50mg/weekly  IM  or 
alternatively  transdermally  in  patches  5  mg/daily. 
The oral route (testosterone undeconate) should be 
avoided due to liver toxicity.
For  pubertal  induction  in  girls  oral 
Ethinylestradiol is preferred at the dose 100 ng/kg/d 
for  6  months,  where  increase  in  breast  size  and 
growth acceleration is noted. This dose is continued 
for  additional  6  months  and  increased  to  200 
ng/kg/d  for  the  subsequent  year.  Therapeutic 
schedule  is  determined  by  the  same  factors  as  in 
boys.  The adult  dose  is  400  ng/kg/d,  where  the 
uterine  size  is  satisfactorily  increased  for  the 
induction of menarche. Induction of puberty can be 
successfully  achieved  by  the  transdermal  use  of 
Estrogens.
Menarche  is  achieved  by  the  addition  of 
Medroxyprogesterone  10  mg/d  for  10  days  when 
the  size  of  the  uterus  exceeds  5  cm.  When 
menstrual  bleeding  occurs  spontaneously  during 
Estrogen treatment, the regime should be adjusted. 
For maintenance of the menstrual cycle the use of 
Estrogens (Conjugated Estrogens 0.625 ή 1.25 mg, 
Ethinyl Estradiol 20 μg) from day 1
st to  25
th and 
Progesterone from day 14
th to 25
th is required. The 
transdermal use of Estradiol και Norethisterone is 
advantageous  due  to  decreased  liver  toxicity  and 
preferred in most cases.  
Normal sexual activity and reproductive capacity 
have become demanding tasks for women with TM. 
Despite  the  presence  of  Hypogonadotrophic 
Hypogonadism and severe iron deposition, ovarian 
function may be preserved, as they are still able to 
increase  oestradiol  level  following  gonadotrophin 
stimulation test and produce ova.
71,72 Women with 
TM  who  are  regularly  transfused  and  are  well 
chelated  become  able  to  conceive  after  a  closely 
monitored  treatment.
63,73 Males  who  have  normal 
gonadal  function  maintain  their  spermatogenic 
ability and therefore, frequently become fathers. On 
the  other  side  of  the  spectrum,  in  cases  where 
impaired spermatogenesis is present, a combination 
treatment with hCG and hMG/ recFSH has proven 
to  be  beneficial  in  improving  their  reproductive 
capacity.
70
Epilogue:  Several  endocrine  glands  may  be 
affected  in  patients  with  TM  in  childhood, 
adolescence and adulthood. Pituitary damage due to 
iron overload is the underlying pathogenetic factor 
in  hypogonadism  and  partly  contributes  to  poor 
growth.  Luckily  these  complications do  not 
adversely  affect  the  life  expectancy  of  these 
individuals.  Close  follow  up  and  proper 
management  is  crucial  for  every  patient.  Early 
recognition of growth disturbance and prevention of 
hypogonadism  by  early  and  judicious  chelation 
therapy is mandatory for the improvement of their 
quality  of  life.  Patients  with  TM  can  now  live  a 
better life due to modern advances in their medical 
care  and  our  better  understanding  in  the 
pathogenesis,  manifestation  and  prevention  of 
endocrine complications.
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